Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Income towards Parent Company (2020 - 2025)

Historic Income towards Parent Company for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$26.3 million.

  • Pliant Therapeutics' Income towards Parent Company rose 5446.74% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$175.5 million, marking a year-over-year increase of 1298.19%. This contributed to the annual value of -$210.3 million for FY2024, which is 3035.16% down from last year.
  • Latest data reveals that Pliant Therapeutics reported Income towards Parent Company of -$26.3 million as of Q3 2025, which was up 5446.74% from -$43.3 million recorded in Q2 2025.
  • Pliant Therapeutics' Income towards Parent Company's 5-year high stood at -$22.8 million during Q2 2021, with a 5-year trough of -$57.8 million in Q3 2024.
  • Moreover, its 5-year median value for Income towards Parent Company was -$37.5 million (2023), whereas its average is -$37.8 million.
  • As far as peak fluctuations go, Pliant Therapeutics' Income towards Parent Company tumbled by 30723.55% in 2021, and later surged by 5446.74% in 2025.
  • Over the past 5 years, Pliant Therapeutics' Income towards Parent Company (Quarter) stood at -$24.5 million in 2021, then tumbled by 42.92% to -$35.1 million in 2022, then decreased by 17.25% to -$41.1 million in 2023, then dropped by 20.98% to -$49.7 million in 2024, then surged by 47.11% to -$26.3 million in 2025.
  • Its Income towards Parent Company stands at -$26.3 million for Q3 2025, versus -$43.3 million for Q2 2025 and -$56.2 million for Q1 2025.